Maui Imaging has secured $14m in a Series D financing round, including equity funding, for supporting the manufacturing, sales, and marketing efforts of its computed echo tomography (CET)-based imaging technology.
Acertara Acoustic Laboratories spearheaded the funding round.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The CET leverages ultrasound to penetrate tissues, enabling quick imaging of the human body. It is protected by more than 160 patents.
The company is now advancing to the commercial stage with devices being delivered to initial users.
Acertara has taken the lead in pre-orders and holds exclusive distributorship rights in the US for hospitals not served directly by Maui Imaging.
Acertara Acoustic Labs president and CEO Levi Moore said: 鈥淭he MAUI ultrasound system represents a major advancement in medical imaging. By reducing the complexity of image acquisition and offering an intuitive approach, it expands ultrasound鈥檚 reach to new users and clinical settings.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData鈥淲e鈥檙e working closely with MAUI to accelerate adoption in hospitals nationwide, where this technology has the potential to save lives and significantly improve patient outcomes.鈥�
In October 2023, the MAUI K3900 ultrasound imaging system secured 510(k) clearance from the US Food and Drug Administration (FDA).
It is designed for a wide range of diagnostic applications, including abdominal, foetal, paediatric, and cardiac imaging.
Maui Imaging’s diagnostic imaging approach offers a blend of ultrasound and CT capabilities without the risks associated with ionising radiation.
The company leverages algorithms that process the reflected energy from different angles and compile the information to generate accurate images of the body’s interior. This method allows the imaging system to incorporate common impediments such as bone, gas, fat, medical instruments, and implants into the final image, rather than allowing them to hinder the imaging process.
Maui Imaging is actively conducting clinical trials with military partners and other organisations to validate this technology.
Last year, Maui Imaging came out of stealth mode, announcing a $4m deal with the US Department of Defense to support trauma response initiatives using its ultrasound device. This deal involved the MAUI K3900 system.
